MARKET

EVGN

EVGN

Evogene
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.880
+0.180
+4.86%
After Hours: 3.990 +0.11 +2.84% 19:53 12/04 EST
OPEN
3.680
PREV CLOSE
3.700
HIGH
4.390
LOW
3.680
VOLUME
2.73M
TURNOVER
--
52 WEEK HIGH
5.30
52 WEEK LOW
0.7500
MARKET CAP
138.03M
P/E (TTM)
-4.7329
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Sutro Biopharma, Merrimack Pharmaceuticals leads healthcare gainers; Precision BioSciences, Cortexyme among major losers
Gainers: Sutro Biopharma (STRO) +33%, Merrimack Pharmaceuticals (MACK) +18%, Evogene (EVGN) +18%, BioCryst Pharmaceuticals (BCRX) +16%, PDS Biotechnology (PDSB) +15%.Losers: Precision BioSciences DTIL -21%, Cortexyme CRTX -17%, Chembio Diagnostics CEMI -14%, Cellectar Biosciences (CLRB) -11%, Inhibrx (INBX) -8%.
Seekingalpha · 22h ago
The Week In Cannabis: Stocks Outperform S&P, Mexico Moves Forward, Earnings, And More
Cannabis stocks outperformed the S&P 500 this week. Over the last five trading days:
Benzinga · 11/21 23:35
SONO, CD, ZTO and LB among after-hours movers
Gainers: [[SONO]] +22.6%. [[LB]] +14.3%. [[LOW]] +8.9%. [[FCEL]] +8.6%. [[AQST]] +6.9%.Losers: [[EVGN]] -14.9%. [[PNNT]] -7.3%. [[ZTO]] -5.8%. [[CD]] -5.5%. [[GPRO]] -5.1%.
Seekingalpha · 11/18 22:56
Lowe's Companies, GoodRx Holdings leads premarket losers' pack
Oncternal Therapeutics (ONCT) -26% after raising 'bought deal' offering to $22.5M.PaySign (PAYS) -25% on Q3 earnings release.Interpace Biosciences (IDXG) -17%.New Concept Energy (GBR) -12%.Alterity Therapeutics (ATHE) -11%.Yunhong CTI (CTIB) -8%.Lowe's Companies (LOW)-6% on Q3 earnings
Seekingalpha · 11/18 13:30
Evogene Ltd. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / November 18, 2020 / Evogene Ltd. (NASDAQ:EVGN) will be discussing their earnings results in their 2020 Third Quarter Earnings call to be held on November 18, 2020 at 9:00 AM Eastern Time.
ACCESSWIRE · 11/18 12:15
Evogene Ltd. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / November 18, 2020 / Evogene Ltd.
ACCESSWIRE · 11/18 12:15
Evogene Q3 EPS $(0.17) Down From $(0.16) YoY
Evogene (NASDAQ:EVGN) reported quarterly losses of $(0.17) per share. This is a 6.25 percent decrease over losses of $(0.16) per share from the same period last year.
Benzinga · 11/18 12:08
Evogene reports Q3 results
Evogene (EVGN): Q3 GAAP EPS of -$0.17.Revenue of $0.32M (+220.0% Y/Y)Press Release
Seekingalpha · 11/18 12:01
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of EVGN. Analyze the recent business situations of Evogene through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average EVGN stock price target is 8.00 with a high estimate of 8.00 and a low estimate of 8.00.
EPS
Institutional Holdings
Institutions: 30
Institutional Holdings: 8.73M
% Owned: 24.55%
Shares Outstanding: 35.57M
TypeInstitutionsShares
Increased
5
4.45M
New
13
-1.69M
Decreased
5
448.85K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Fishing & Farming
+1.27%
Food & Tobacco
+1.41%
Key Executives
Chairman/Director
Martin Gerstel
President/Chief Executive Officer
Ofer Haviv
Chief Financial Officer
Alex Taskar
Executive Vice President
Ido Dor
Executive Vice President
Mark Kapel
Executive Vice President
Eran Kosover
Chief Technology Officer
Hagai Karchi
Vice President
Arnon Heyman
Vice President
Alin Sela-Brown
Director
Adrian Percy
Director
Oded Shoseyov
Independent Director
Sarit Firon
Independent Director
Ziv Kop
Independent Director
Kinneret Livnat Savitsky
Independent Director
Adina Makover
Independent Director
Leon Recanati
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About EVGN
Evogene Ltd. (Evogene) is a biotechnology company for the improvement of crop productivity. The Company is engaged in developing seed traits for improved yield and abiotic stress tolerance, seed traits for biotic stress resistance, herbicides and bio-stimulants. The Company operates a seed business under its subsidiary Evofuel Ltd. (Evofuel). It operates through two segments. Its Evogene segment develops seed traits, ag-chemical products, and ag-biological products to improve plant performance. The Company's Evofuel segment develops species of the castor bean plant for second generation feedstock for biofuel and other industrial uses. Its Crop Enhancement (CE) division is developing two types of products: CE seed traits, are seed traits having improved yield and abiotic stress tolerance, and ag-biologicals, which focuses on microbial-based bio-stimulants. The Company's Crop Protection (CP) division is developing two types of products: CP seed traits and ag-chemicals.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Evogene Ltd stock information, including NASDAQ:EVGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EVGN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EVGN stock methods without spending real money on the virtual paper trading platform.